# Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

> **NCT03112174** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 366 (actual)

## Conditions studied

- Mantle-Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Venetoclax
- **DRUG:** Placebo Oral tablet to match Venetoclax

## Key facts

- **NCT ID:** NCT03112174
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-19
- **Primary completion:** 2024-06-26
- **Final completion:** 2024-06-27
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03112174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03112174, "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03112174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*